{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:08:00Z","timestamp":1785229680807,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cmi.2024.12.008","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T11:44:29Z","timestamp":1734090269000},"page":"534-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimization of antiviral dosing in Herpesviridae encephalitis: a promising approach to improve outcome?"],"prefix":"10.1016","volume":"31","author":[{"given":"Roland","family":"Nau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Seele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Bodilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Gro\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.12.008_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1017\/S0950268811000483","article-title":"Herpes simplex encephalitis and management of acyclovir in encephalitis patients in France","volume":"140","author":"Stahl","year":"2012","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.cmi.2024.12.008_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/v11020103","article-title":"Current in\u00a0vitro models to study varicella zoster virus latency and reactivation","volume":"11","author":"Baird","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2024.12.008_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijid.2019.02.045","article-title":"Cytomegalovirus encephalitis in immunocompetent infants: a 15-year retrospective study at a single center","volume":"82","author":"Guo","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.008_bib4","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/CMR.00105-19","article-title":"Immunomodulatory strategies in herpes simplex virus encephalitis","volume":"33","author":"Piret","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2024.12.008_bib5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1474-4422(18)30244-8","article-title":"Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis","volume":"17","author":"Armangue","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cmi.2024.12.008_bib6","series-title":"Physiology and pathophysiology of the cerebrospinal fluid","author":"Davson","year":"1987"},{"key":"10.1016\/j.cmi.2024.12.008_bib7","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2024.12.008_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40263-024-01082-3","article-title":"CNS viral infections-what to consider for improving drug treatment: a plea for using mathematical modeling approaches","volume":"38","author":"Sun","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.cmi.2024.12.008_bib9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12974-022-02538-3","article-title":"Spatial and temporal variation of routine parameters: pitfalls in the cerebrospinal fluid analysis in central nervous system infections","volume":"19","author":"Djukic","year":"2022","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.cmi.2024.12.008_bib10","doi-asserted-by":"crossref","first-page":"134475","DOI":"10.1016\/j.neulet.2019.134475","article-title":"Cell-type specific differences in antiretroviral penetration and the effects of HIV-1 Tat and morphine among primary human brain endothelial cells, astrocytes, pericytes, and microglia","volume":"712","author":"Patel","year":"2019","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.cmi.2024.12.008_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.11.002","article-title":"Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis","volume":"149","author":"Quenelle","year":"2018","journal-title":"Antivir Res."},{"key":"10.1016\/j.cmi.2024.12.008_bib12","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/v12111294","article-title":"Differential efficacy of novel antiviral substances in 3D and monolayer cell culture","volume":"12","author":"Koban","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2024.12.008_bib13","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s44321-024-00039-9","article-title":"Organotypic culture of human brain explants as a preclinical model for AI-driven antiviral studies","volume":"16","author":"Partiot","year":"2024","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cmi.2024.12.008_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcv.2018.08.005","article-title":"Comparing molecular quantification of herpes simplex virus (HSV) in cerebrospinal fluid (CSF) with quantitative structural and functional disease severity in patients with HSV encephalitis (HSVE): implications for improved therapeutic approaches","volume":"107","author":"Ramirez","year":"2018","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.cmi.2024.12.008_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000351521","article-title":"Determination of viral load by quantitative real-time PCR in herpes simplex encephalitis patients","volume":"57","author":"Bhullar","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.cmi.2024.12.008_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2019.01.008","article-title":"In\u00a0vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review","volume":"163","author":"Chemaly","year":"2019","journal-title":"Antivir Res."},{"key":"10.1016\/j.cmi.2024.12.008_bib17","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1128\/AAC.49.11.4671-4680.2005","article-title":"Organotypic epithelial raft cultures as a model for evaluating compounds against alphaherpes viruses","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/pharmaceutics15010163","article-title":"Optimizing antiviral dosing for HSV and CMV treatment in immunocompromised patients","volume":"15","author":"Huntjens","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cmi.2024.12.008_bib19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0732-8893(87)90005-8","article-title":"Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy","volume":"7","author":"Bean","year":"1987","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.008_bib20","doi-asserted-by":"crossref","first-page":"113852","DOI":"10.1016\/j.biopha.2022.113852","article-title":"Therapeutic monitoring of serum concentrations of acyclovir and its metabolite 9-(carboxymethoxymethyl) guanine in routine clinical practice","volume":"156","author":"Kacirova","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cmi.2024.12.008_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003495-199447010-00009","article-title":"A\u00a0reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy","volume":"47","author":"Wagstaff","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2024.12.008_bib22","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/pharmaceutics14112311","article-title":"Shedding a light on acyclovir pharmacodynamics: a retrospective analysis on pharmacokinetic\/pharmacodynamic modelling of acyclovir for the treatment of varicella zoster virus infection in immunocompromised patients: a pilot study","volume":"14","author":"Grit","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cmi.2024.12.008_bib23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/jac\/dkab419","article-title":"Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads","volume":"77","author":"M\u00e4rtson","year":"2022","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/jac\/dkl067","article-title":"The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment","volume":"57","author":"Helld\u00e9n","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/jac\/24.6.947","article-title":"Acyclovir concentrations in serum and cerebrospinal fluid at steady state","volume":"24","author":"Lycke","year":"1989","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib26","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jiac.2022.03.022","article-title":"Serum and cerebrospinal fluid acyclovir pharmacokinetics in a neonate with HSV-2 meningoencephalitis","volume":"28","author":"Shoji","year":"2022","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib27","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1128\/AAC.00729-09","article-title":"Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function","volume":"54","author":"Smith","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib28","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1128\/AAC.47.8.2438-2441.2003","article-title":"Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir","volume":"47","author":"Lycke","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib29","first-page":"2015","article-title":"Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment","author":"Peredo","year":"2015","journal-title":"a Case Study BMJ Case Rep"},{"key":"10.1016\/j.cmi.2024.12.008_bib30","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/tid.12579","article-title":"Viral load and ganciclovir (GCV) concentration in cerebrospinal fluid of patients successfully treated with GCV or valGCV for human herpesvirus 6 encephalitis\/myelitis following umbilical cord blood transplantation","volume":"18","author":"Morita","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.008_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13052-015-0132-8","article-title":"Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection","volume":"41","author":"Natale","year":"2015","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.cmi.2024.12.008_bib32","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1128\/AAC.37.9.1777","article-title":"Penetration of foscarnet into cerebrospinal fluid of AIDS patients","volume":"37","author":"Raffi","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib33","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1128\/AAC.33.7.1023","article-title":"Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection","volume":"33","author":"Sj\u00f6vall","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib34","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.37.5.1010","article-title":"Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis","volume":"37","author":"Hengge","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/jac\/dkad117","article-title":"Cerebrospinal fluid concentration of foscarnet in patients with HHV-6 encephalitis after haematopoietic stem cell transplantation","volume":"78","author":"Irie","year":"2023","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0002-9343(82)90084-5","article-title":"Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals","volume":"73","author":"Whitley","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2024.12.008_bib37","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1021\/ci700257y","article-title":"Computation of octanol-water partition coefficients by guiding an additive model with knowledge","volume":"47","author":"Cheng","year":"2007","journal-title":"J\u00a0Chem Inf Model"},{"key":"10.1016\/j.cmi.2024.12.008_bib38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s002800050916","article-title":"Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates","volume":"43","author":"Serabe","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cmi.2024.12.008_bib39","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jcpt.13464","article-title":"Neurotoxicity associated with acyclovir and valacyclovir: a systematic review of cases","volume":"46","author":"Brandariz-Nu\u00f1ez","year":"2021","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.cmi.2024.12.008_bib40","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1128\/AAC.01023-10","article-title":"Valacyclovir for herpes simplex encephalitis","volume":"55","author":"Pouplin","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib41","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1128\/AAC.38.7.1534","article-title":"Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease","volume":"38","author":"Jacobson","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib42","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/jac\/dky568","article-title":"Valaciclovir therapy for herpes encephalitis: caution advised","volume":"74","author":"Bodilsen","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s13318-021-00733-w","article-title":"Acyclovir brain disposition: interactions with P-gp, Bcrp, Mrp2, and Oat3 at the blood-brain barrier","volume":"47","author":"Shan","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.cmi.2024.12.008_bib44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3851\/IMP3313","article-title":"Acute renal failure related to high doses of acyclovir (15 mg\/kg\/8 h) during treatment of varicella zoster virus encephalitis","volume":"24","author":"Martinot","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2024.12.008_bib45","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/jac\/dkq516","article-title":"Antibiotic dosing in critical illness","volume":"66","author":"McKenzie","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib46","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ369","article-title":"Herpes simplex encephalitis: lack of clinical benefit of long-term valacyclovir therapy","volume":"61","author":"Gnann","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.008_bib47","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1542\/peds.108.2.230","article-title":"Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections","volume":"108","author":"Kimberlin","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.cmi.2024.12.008_bib48","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1093\/clinids\/10.Supplement_3.S507","article-title":"Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function","volume":"10","author":"Sommadossi","year":"1988","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.008_bib49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00042560-199803010-00007","article-title":"Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects","volume":"17","author":"Cimoch","year":"1998","journal-title":"J\u00a0Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1016\/j.cmi.2024.12.008_bib50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/dmd.114.059840","article-title":"Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma","volume":"43","author":"Gynther","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cmi.2024.12.008_bib51","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1208\/s12248-017-0050-3","article-title":"Microdialysis: the key to physiologically based model prediction of human CNS target site concentrations","volume":"19","author":"Yamamoto","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.cmi.2024.12.008_bib52","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/jac\/dkae098","article-title":"Continuous evaluation of single-dose moxifloxacin concentrations in brain extracellular fluid, cerebrospinal fluid, and plasma: a novel porcine model","volume":"79","author":"Mariager","year":"2024","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.12.008_bib53","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3390\/antibiotics11101293","article-title":"A\u00a0minimal physiologically based pharmacokinetic model to characterize CNS distribution of metronidazole in neuro care ICU patients","volume":"11","author":"Chauzy","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2024.12.008_bib54","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-024-01363-6","article-title":"Predictions of bedaquiline central nervous system exposure in patients with tuberculosis meningitis using physiologically based pharmacokinetic modeling","volume":"63","author":"Mehta","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2024.12.008_bib55","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1128\/JVI.79.12.7721-7727.2005","article-title":"[18F]FHPG positron emission tomography for detection of herpes simplex virus (HSV) in experimental HSV encephalitis","volume":"79","author":"Buursma","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cmi.2024.12.008_bib56","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1093\/infdis\/jiad247","article-title":"Advances and challenges in molecular imaging of viral infections","volume":"228","author":"Lau","year":"2023","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.008_bib57","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.cmi.2020.09.031","article-title":"Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis","volume":"27","author":"Westman","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.12.008_bib58","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s13365-020-00889-2","article-title":"Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus","volume":"26","author":"Tyrberg","year":"2020","journal-title":"J\u00a0Neurovirol"},{"key":"10.1016\/j.cmi.2024.12.008_bib59","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3390\/cells13141208","article-title":"HSV-1 and cellular miRNAs in CSF-derived exosomes as diagnostically relevant biomarkers for neuroinflammation","volume":"13","author":"Scheiber","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.cmi.2024.12.008_bib60","doi-asserted-by":"crossref","first-page":"1238149","DOI":"10.3389\/fncel.2023.1238149","article-title":"Septic encephalopathy in the elderly - biomarkers of potential clinical utility","volume":"17","author":"Sch\u00fctze","year":"2023","journal-title":"Front Cell Neurosci"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24005949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24005949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T02:29:51Z","timestamp":1775010591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24005949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1198743X24005949"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.12.008","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of antiviral dosing in Herpesviridae encephalitis: a promising approach to improve outcome?","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}